Millipore Sigma Vibrant Logo

116890 Adenosine Kinase Inhibitor - CAS 214697-26-4 - Calbiochem

116890
가격 및 재고 조회

개요

Replacement Information

주요 사양표

CAS #Empirical Formula
214697-26-4C₂₂H₁₉BrN₆O

가격 및 재고여부

카탈로그 번호 재고 정보패킹 포장 단위 가격(VAT 별도) 수량
116890-5MGCN
재고 정보 검색...
재고 없음재고 없음
예상 출고 가능일 
단종품
제한된 수량 가능
재고여부 확인
    Remaining: will advise
      Remaining: will advise
      추천사항
      고객 서비스로 문의
      Contact Customer Service

      Plastic ampoule 5 mg
      가격 검색...
      가격을 검색할 수 없습니다
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      가격 문의 추가 정보
      ()이 할인됨
       
      가격 문의
      Description
      OverviewA cell-permeable, non-nucleoside pyridopyrimidine compound that acts as a potent, adenosine-competitive, and reversible adenosine kinase (AK) inhibitor (IC50 = 50.7 nM using intact IMR-32 cells and 1.7 nM in cell-free assays using rat brain cytosolic AK). The inhibitory effect is not species-specific and its pharmacological selectivity is confirmed using a panel of more than 80 other enzymes, ion channels, and receptors, including various adesine receptors. It readily crosses the blood-brain barrier and is shown to be efficacious in in vivo animal models via various administration methods (i.p., p.o., s.c.).

      Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without salt molecules.
      Catalogue Number116890
      Brand Family Calbiochem®
      Synonyms4-Amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, 2HCl, ABT-702
      References
      ReferencesDe Vry, J., et al. 2004. Eur. J. Pharmacol. 491, 137.
      Suzuki, R., et al. 2001. Br. J. Pharmacol. 132, 1615.
      Boyle, D.L., et al. 2001. J. Pharmacol. Exp. Ther. 296, 495.
      Kowaluk, E.A., et al. 2000. J. Pharmacol. Exp. Ther. 295, 1165.
      Jarvis, M.F., et al. 2000. J. Pharmacol. Exp. Ther. 295, 1156.
      Product Information
      CAS number214697-26-4
      ATP CompetitiveN
      FormYellow to orange solid
      Hill FormulaC₂₂H₁₉BrN₆O
      Chemical formulaC₂₂H₁₉BrN₆O
      Hygroscopic Hygroscopic
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetAdenosine Kinase
      Primary Target IC<sub>50</sub>50.7 nM inhibiting adenosine kinase (AK) using intact IMR-32 cells and 1.7 nM in cell-free assays using rat brain cytosolic AK
      Purity≥90% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Adenosine Kinase Inhibitor - CAS 214697-26-4 - Calbiochem MSDS

      타이틀

      물질안전보건자료(MSDS) 

      Adenosine Kinase Inhibitor - CAS 214697-26-4 - Calbiochem Certificates of Analysis

      TitleLot Number
      116890

      References

      참고문헌 보기
      De Vry, J., et al. 2004. Eur. J. Pharmacol. 491, 137.
      Suzuki, R., et al. 2001. Br. J. Pharmacol. 132, 1615.
      Boyle, D.L., et al. 2001. J. Pharmacol. Exp. Ther. 296, 495.
      Kowaluk, E.A., et al. 2000. J. Pharmacol. Exp. Ther. 295, 1165.
      Jarvis, M.F., et al. 2000. J. Pharmacol. Exp. Ther. 295, 1156.

      Brochure

      Title
      Biochromatography Portfolio Guide (MM)
      Fractogel Chromatography Resin - Capture your Target with Speed and Efficiency

      Technical Info

      Title
      Article: Viral clearance in antibody purification using tentacle ion exchangers

      Posters

      Title
      Tentacle cation exchangers for optimized mAb purification: Understanding the relationship between tentacle chemistries and resin performance
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision17-December-2018 JSW
      Synonyms4-Amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, 2HCl, ABT-702
      DescriptionA cell-permeable, non-nucleoside pyridopyrimidine compound that acts as a potent, adenosine-competitive, and reversible adenosine kinase (AK) inhibitor (IC50 = 50.7 nM using intact IMR-32 cells and 1.7 nM in cell-free assays using rat brain cytosolic AK). The inhibitory effect is not species-specific and its pharmacological selectivity is confirmed using a panel of more than 80 other enzymes, ion channels, and receptors, including various adesine receptors. It readily crosses the blood-brain barrier and is shown to be efficacious in in vivo animal models via various administration methods (i.p., p.o., s.c.).
      FormYellow to orange solid
      CAS number214697-26-4
      Chemical formulaC₂₂H₁₉BrN₆O
      Structure formulaStructure formula
      Purity≥90% by HPLC
      SolubilityDMSO (20 mg/ml)
      Storage +2°C to +8°C
      Hygroscopic
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesDe Vry, J., et al. 2004. Eur. J. Pharmacol. 491, 137.
      Suzuki, R., et al. 2001. Br. J. Pharmacol. 132, 1615.
      Boyle, D.L., et al. 2001. J. Pharmacol. Exp. Ther. 296, 495.
      Kowaluk, E.A., et al. 2000. J. Pharmacol. Exp. Ther. 295, 1165.
      Jarvis, M.F., et al. 2000. J. Pharmacol. Exp. Ther. 295, 1156.